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Abstract 
During apoptosis, hundreds of proteins are cleaved by caspases, most of them by 
the executioner caspase-3. However, caspase-7, which shares the same substrate 
primary sequence preference as caspase-3, is better at cleaving poly(ADP-ribose) 
polymerase 1 (PARP) and Hsp90 co-chaperone p23, despite a lower intrinsic 
activity. Here, we identify key lysine residues (K38KKK) within the N-terminal 
domain (NTD) of caspase-7 as critical elements for the efficient proteolysis of 
these two substrates. Caspase-7’s NTD binds PARP and improves its cleavage by 
a chimeric caspase-3 by ~30-fold. Cellular expression of caspase-7 lacking the 
critical lysine residues resulted in less efficient PARP and p23 cleavage compared 
to cells expressing the wild-type peptidase. We further show using a series of 
caspase chimeras the positioning of p23 on the enzyme providing us with a 
mechanistic insight into the binding of the exosite. In summary, we have 
uncovered a role for the NTD and the N-terminal peptide of caspase-7 in 
promoting key substrate proteolysis. 
 
\body 
Introduction 
Apoptosis employs a family of cysteinyl peptidases, the caspases, to integrate and 
propagate various signals to cause cell demise. The latter step is governed by a 
subgroup of caspases named executioners that are responsible for the cleavage of a 
plethora of cellular proteins. The cleavage of some of these proteins provokes the 
associated hallmarks of apoptosis (1, 2). A survey of the published literature suggests 
that, among executioners, caspase-3 performs the bulk of the cleavage events. These 
data are in agreement with biochemical studies suggesting that this caspase is highly 
active and is present at the highest concentration among all caspases in most cells (3-
5). For these reasons, caspase-3 supersedes other caspases in most biochemical 
readouts (4). 
Caspase-3 and -7 share 57% sequence identity throughout their catalytic 
domains. Additionally, they have the same substrate preference based on studies using 
peptide substrate libraries (6, 7). Despite this apparent redundancy, they have an 
overlapping but non-redundant substrate repertoire. For instance, ROCK1, α-fodrin and 
Rho-GDI are cleaved efficiently by both caspases (8, 9). However, ICAD (9), the XIAP 
(X-linked inhibitor of apoptosis protein) (10) and initiator caspase-9 (11) are preferred by 
caspase-3, whereas Nogo-B (12), ataxin-7 (13), and the p23 co-chaperone (9) are 
cleaved more efficiently by caspase-7. PARP-1 [poly(ADP-ribose) polymerase 1], the 
first caspase substrate identified (14), is a particularly interesting death substrate, and its  
cleavage is now recognized as a hallmark of apoptosis. PARP-1 proteolysis is essential 
for an adequate energetic balance during apoptosis and protects against necrosis (15, 
16). Previous work has suggested that caspase-7 is responsible for PARP inactivation 
during apoptosis (17), but no mechanism for such selectivity has been proposed. 
However, many caspases and the immune-derived granzymes have been suggested to 
cleave PARP (14, 17-21). Notably, whereas PARP-1 is cleaved at a canonical 
caspase-3/7 site (DEVD↓G), p23 is cleaved at a less suitable site (PEVD↓G). Indeed, 
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studies have shown that a proline instead of an aspartate in the P4 position reduces the 
catalysis of caspase-7 by 16,500-fold (7). 
In the present study, we hypothesized that if caspase-7 is better at cleaving 
certain death substrates such as PARP and p23 despite the fact that it is intrinsically 
less active than caspase-3, it must use exosites to improve catalysis. This attractive 
possibility has been raised several times in the past decade (22-25), but never 
confirmed. Our results show that the N-terminal domain (NTD) of caspase-7 contains a 
conserved basic patch that greatly improves substrate recognition and proteolysis of 
both death substrates. This study provides a unique demonstration of the use of a 
substrate exosite by a caspase. 
 
Results 
Caspase-7 cleaves PARP and p23 more efficiently than caspase-3. To determine 
whether caspase-7 or caspase-3 is the more efficient protease at cleaving death 
substrates, we performed assays in which active site-titrated recombinant caspases 
were incubated with cell extracts from MCF-7 cells (which lack caspase-3) expressing a 
short hairpin RNA against caspase-7 (Supplementary Fig. 1A). In these conditions, the 
ectopic caspase faces a mixture of substrates, akin to the cellular context. Furthermore, 
at the concentration used, caspase-7 cannot activate other caspases (26). When 
various concentrations of caspase-7 or -3 were incubated with the extracts, the 116 kDa 
full-length PARP was cleaved by both enzymes to yield the typical 89 kDa fragment 
detected by our antibody (Fig. 1A). However, whereas 5 nM caspase-7 was sufficient to 
process > 85% of PARP, 50 nM caspase-3 resulted in less than 40% conversion. We 
also examined the cleavage of p23 and found that caspase-7 cleaves this protein more 
efficiently than caspase-3, albeit with less efficacy than PARP (Fig. 1B). To ensure that 
our assays were unbiased towards caspase-7, we analyzed ICAD and recombinant 
caspase-9 proteolysis and found that caspase-3 is better at cleaving both proteins (Fig. 
1C,D). These results demonstrate that each of these executioner caspases prefers a 
different set of death substrates. 
 Comparison of the activity of these enzymes using the small fluorogenic substrate 
AcDEVD-Afc yielded catalytic specificity constants (kcat/KM) for caspase-7 and -3 of 1.1 x 
105 and 5.9 x 105 M-1s-1, respectively (Supplementary Table SI), which are in agreement 
with previously published work (4, 26, 27). To determine whether the observed 
difference was an artifact of using a peptidic substrate, we used the baculovirus caspase 
inhibitor p35 with the inactivating C2A mutation that turns this protein into a substrate 
(28, 29). Similar to AcDEVD-Afc, p35-C2A is cleaved ~5 times more efficiently by 
caspase-3 than by caspase-7 (Fig. 1E), suggesting that caspase-3 is indeed a more 
proficient enzyme. We also tested the activity of caspase-3 and -7 on AcPEVD-Afc, 
which features the same cleavage site motif as that in p23, and found that caspase-3 is 
~500 times more active than caspase-7 (Supplementary Table SI). Finally, to ensure 
that the preference for PARP we observed is not caused by the presence of competing 
substrates or endogenous caspase inhibitors such as XIAP, we performed assays using 
antibody-purified PARP (Fig. 1F). However, we still found that caspase-7 was more 
efficient than caspase-3 at cleaving purified PARP, demonstrating the robustness of our 
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assays. Taken together, these results suggest that caspase-7 likely uses an exosite to 
promote PARP and p23 cleavage. 
The mature NTD of caspase-7 promotes PARP cleavage. The catalytic domain of 
caspase-3 and -7 is highly similar. However, the N-terminal region that precedes the 
catalytic domain is much longer in caspase-7; this region, therefore, is a good exosite 
candidate. Consequently, we tested the ability of a caspase-7 variant that lacked part of 
its NTD to cleave PARP. We took advantage of an alternate translation initiation site 
within the NTD (Met45; Fig. 2A) to generate an active enzyme (26). M45-caspase-7 is 
less efficient at cleaving PARP than wild-type (WT) enzyme at identical concentrations 
(Fig. 2B), even though it is as active on the peptidic substrate (Supplementary Table 
SI). The percentage of PARP cleavage was estimated using imaging software as 
described in Supporting information and reported in Supplementary Fig. 2. Specifically, 
we compared the intensity of the full-length 116-kDa protein because the cleaved 
fragments have variable detectability and stability as suggested for many caspase 
substrate cleavage products including PARP (30). By readjusting the caspase 
concentration and incubation time, we were able to estimate that proteolysis of PARP by 
caspase-7 is nearly 8 times higher than that by caspase-3, and that the cleavage rate by 
truncated M45-caspase-7 was less than 2 x 104 M-1s-1, which is ~30 times lower than the 
rate by WT caspase-7 (Fig. 2C). We then took advantage of the conserved methionine 
residue (Met62 in caspase-7 and Met39 in caspase-3) located just N-terminal to the 
catalytic domain to swap the NTD of caspase-7 with that of caspase-3 (casp3:casp7; 
Fig. 2B). This transfer failed to restore PARP cleavage, demonstrating that the ability is 
specific to caspase-7’s NTD. Notably, casp3:casp7 is fully active and processes its N-
peptide (Supplementary Table SI and Supplementary Fig. 3). Conversely, we tested the 
ability of the NTD of caspase-7 to confer PARP cleavage proficiency to caspase-3 (gain 
of function) by designing a casp7:casp3 chimera (Fig. 2D). In our assay, this chimeric 
caspase was as efficient as caspase-7 at cleaving PARP. Kinetic analysis demonstrated 
that casp7:casp3 was 3.6- and 30-fold more efficient than caspase-7 and WT 
caspase-3, respectively (compare Fig. 2E vs. Fig. 2C). Furthermore, no alteration in the 
proteolysis of ICAD, a caspase-3-preferred substrate, was observed for this caspase-3 
chimera (Supplementary Fig. 4). 
Because removal of caspase-7’s N-peptide precedes its activation (31), we asked 
if its removal was necessary to the function of the exosite. Thus, we compared a 
caspase-7 mutant that cannot process its N-peptide due to a D23A mutation (26) and 
found that this mutant is unable to cleave PARP in our standard assay (Fig. 2F). 
Importantly, caspase-7D23A does not impair catalytic activity [Supplementary Table SI 
and (26)]. These results demonstrate that the NTD of caspase-7 contains molecular 
determinants that promote efficient PARP proteolysis. 
A basic patch in caspase-7’s NTD is critical to promote PARP cleavage. We wanted 
to identify the critical residues within the NTD that constitute the exosite. To this end, we 
tested the ability of deletion mutants to cleave PARP. Caspase-7 deletion mutants that 
lacked NTD residues downstream of Phe36 failed to process PARP in the assay 
conditions used (Fig. 3A). Conversely, a caspase-7 variant missing residues up to Val32 
was still able to cleave the substrate. We also tested tetra-alanine substitution mutants 
(Fig. 3B) and found that changing residues 37-40 to alanine (mutant 4A4) had a 
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dramatic effect on PARP proteolysis. These two sets of results suggest that the exosite 
is present in the basic sequence contained within the NTD. We then fine tuned our 
assay by lowering the incubation time and caspase concentration to detect the influence 
of individual residues and scanned the residues contained in the 4A4 mutant (Ser37-
Lys40) plus the following Lys41 (Fig. 3C). Unlike the mutation of Ser37, mutation of any 
lysine hampered, but did not abrogate, PARP cleavage, and K39A and K40A mutations 
had the greatest effect. The latter result suggests that charge within the exosite is the 
main determinant. Finally, to further characterize the motif, we designed four mutants 
with altered charges: K38KKK→AAAA (different from the 4A4 mutant), →KAAK, →KEKK 
and →KEEK (Fig. 3D). From now on, all K38KKK mutations are referred to using 
subscript of the four replacing amino acids (WT is caspase-7KKKK). Compared to WT 
caspase-7, caspase-7KAAK was as efficient at cleaving PARP, whereas a decrease in 
efficacy was observed as the net charge decreased and negative charges were added. 
Indeed, caspase-7KEKK was worse than caspase-7KAAK, although both have the same net 
charge. These results demonstrate that the exosite relies on at least two lysine residues 
and does not tolerate negative charges. Importantly, all tested mutants displayed 
proteolytic activity against the peptide substrate that was either similar to the WT 
enzyme or, if different, could not account for the change in PARP proteolysis 
(Supplementary Table SI). 
With the ability to transfer the exosite on caspase-3, these latest results suggest 
that the exosite is fully contained within the NTD. To further support this conclusion, we 
performed GST (glutathione-S-transferase) pull-down assays using only caspase-7 
residues 24-62. Although GST alone and the tetra-alanine NTD mutant (NTDAAAA) fused 
to GST failed to bind PARP, the WT NTD readily precipitated PARP (Supplementary 
Fig. 5). Indeed, quantification of the immunoblot signal revealed that 38% of PARP was 
pulled down. This result was also confirmed by analysis of the post-pull-down 
supernatant that showed > 50% depletion of PARP. These results show that the NTD 
contains a complete exosite for PARP. 
The NTD of caspase-7 promotes death substrates cleavage in cells. To 
demonstrate that the exosite supports efficient cleavage of PARP in living cells, we 
transfected AD-293 cells stably expressing a short hairpin RNA (shRNA; 293sh7) against 
caspase-7 (Supplementary Fig. 1B) with cDNAs encoding shRNA-resistant flag-tagged 
caspase-7, caspase-7AAAA or a caspase-7 baring the catalytic mutation C285A. In this 
paradigm, caspase-7 self-activates and induces cell death without the contribution of 
any other caspase (26, 32). These constructs also feature the deletion of the N-terminal 
peptide (M23) to mimic its removal by caspase-3. In agreement with our in vitro assays, 
the K38KKK->AAAA mutation decreases PARP proteolysis (Fig. 4A). Albeit less 
pronounced than for PARP cleavage, quantification of cleavage products did revealed a 
decrease of 39% and 26% in the processing of p23 by M23AAAA and Caspase-7AAAA, 
respectively, compared to the corresponding protein bearing an intact exosite. 
Importantly, the capacity of caspase-7AAAA to self-activate was assessed by labeling the 
active enzyme with the activity-based probe biotinyl-VAD-fmk prior to lysis 
(Supplementary Fig. 6). Using this approach, we showed that mutation of the exosite did 
not impede M23-caspase-7AAAA to self-activate, but did alter full-length processing, 
which suggests an interaction between the N-terminal peptide and the exosite. 
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 We also used the death ligand Trail to activate the extrinsic pathway in 293sh7 
cells expressing caspase-7 or caspase-7AAAA at protein levels that do not provoke their 
autoactivation (Fig. 4B). Using this physiologic death stimulus, cells expressing 
caspase-7AAAA did processed PARP to a lesser extent compared to cells expressing the 
WT caspase. Furthermore, time-course of Trail-induced apoptosis showed a 30-60 min 
delayed in PARP cleavage, but no change in caspase-7 cleavage profile (Fig. 4C). 
Processing of p23 was also negatively affected by the exosite mutation. 
Finally, we used cell-free extracts from 293sh7 cells expressing C-terminally flag-
tagged WT and caspase-7AAAA, in which we induced caspase activation by the addition 
of cytochrome c (cytc) and dATP leading to the initiator caspase-9 activation. As a 
source of PARP, we added dialyzed detergent extract from MCF-7sh7 cells. Time-course 
experiments showed a delay in the processing of PARP in extracts reconstituted with 
caspase-7AAAA (Fig. 4D). 
Efficient cleavage of p23 requires the exosite. In Fig. 1, we showed that p23 is 
preferentially cleaved by caspase-7. Consequently, we wanted to extend our finding to 
p23 by analyzing the ability of key mutants of both executioner caspases to cleave 
fluorescein-labeled recombinant p23. Importantly, p23 labeling on free amines did not 
impair p23 cleavage by caspase-7 (Supplementary Fig. 7). In an assay in which WT 
caspase-7 cleaves > 80% of p23, neither M45-caspase-7 nor caspase-3 processed p23 
to the cleaved fragments (Fig. 5A). As we have shown for PARP, the casp7:casp3 
chimera more efficiently cleave p23. A decrease in p23 cleavage was also observed in 
cellular experiments expressing caspase-7AAAA (Fig. 4A,C). These latest results 
demonstrate that caspase-7 also uses the exosite for p23 proteolysis. However, unlike 
PARP, p23 failed to precipitate with GST-NTD suggesting that the interaction between 
the NTD and p23 is much weaker.  
In order to build a model for the interaction of the caspase-7’s exosite with a 
substrate, we sought to identify regions for which mutations interfere with the cleavage 
of p23. We used p23 because 1) it is a smaller protein than PARP, 2) cleavage is much 
slower, which allows us to easily fine tuned the assay, and 3) the exosite is not as 
dominant as it is the case for PARP, which allows us to better appreciate interference by 
other region. We built a rational caspase-7 mutant library that incorporated groups of 
residues that were different in caspase-3 (Supplementary Fig. 8). This mutagenesis 
strategy is very conservative because both executioners share high sequence identity 
and have identical fold, thus limiting potential adverse effect of mutations. Indeed, all but 
one (mut8) of the designed mutants are active and self-activate in bacteria 
(Supplementary Table SI). We tested this series of mutants under conditions in which 
only partial p23 cleavage is obtained. We identified six mutants (mut2, 6, 19, 24, 26, 28) 
with diminished proteolysis of p23 (Fig. 5B, orange arrows). Mutants 6 
(K92DAEAVDAAN) and 19 (S234PGRNSKD) are particularly interesting because 
they are ~0.5 and ~3 times, respectively, more active than WT caspase-7 on the 
fluorogenic substrate, yet ineffective at processing p23. Remarkably, these two mutants 
map to the back of the P4 substrate-binding pocket (Fig. 5C). We also identified mutants 
(mut10, 16, 25, 27) with higher activity toward p23 (Fig. 5B, green arrows). One of them, 
mut25 (Q276SDFSF), mapped to the so-called L4 loop, is even less effective at 
cleaving the peptidic substrate, yet has improved activity on p23. Two more mutants 
Boucher et al. 2012 
 
 7 
(mut10, 16) with higher efficiently on p23, localized on the front side of the caspase 
large subunit enzyme (Fig. 5C). These results suggest that the globular domain of p23 
lies close to the catalytic site while binding to the exosite. 
 
Discussion 
At minimum, caspases select their substrates based on the structural accessibility of a 
P1 aspartate motif. To be efficient, however, more determinants are required to restrict 
the list of candidate proteins. Concretely, initiator caspases must rapidly activate 
downstream executioner caspases, which then must select among the much larger pool 
of death substrates to induce cell death. To this end, cells have evolved proficient 
enzymes, more discriminatory motifs, and presented optimal cleavage sites in flexible 
loops. In many proteolytic systems, further proficiency is achieved through the usage 
exosites. 
 Our results clearly demonstrate that caspase-7 uses a basic patch located in its 
NTD to improve the proteolysis of PARP and p23, two death substrates. This motif is 
conserved in mammals, frog and chicken but not in other birds and fish. This domain is 
whole because it is transferable to another caspase and can precipitate PARP from a 
cell lysate. The improvement bestowed by the NTD is non-trivial because we observed a 
~30-fold decrease in cleavage efficacy when the NTD was removed from caspase-7 and 
a similar change (~30-fold), but in the opposite direction, upon its transfer onto 
caspase-3. Furthermore, the fact that lysine mutants and truncated caspase-7 proteins 
have similar enzymatic properties on the peptidic substrate compared to the WT enzyme 
argues against an allosteric model involving the NTD. Consequently, we conclude that 
the tetra-basic motif fulfills all of the requirements of an exosite. This discovery gives 
credence to a recent study in which it was demonstrated that caspases could not reach 
proficiency solely by presenting a good cleavage motif (22). Indeed, engineering the 
best known cleavage motif (DEVD↓G) into a flexible loop in the small subunit of E. coli 
carA protein resulted in a cleavage efficiency by caspase-3 of ~5 x 104 M-1s-1, which is 
lower than the cleavage rate observed for PARP with caspase-7, an intrinsically less 
active enzyme. By comparing the pool of evolutionary unrelated substrates found in the 
above-mentioned study with the higher cleavage rates of some natural caspase 
substrates, the authors concluded that caspases likely use exosites to increase 
catalysis. Another important finding of our study is that the exosite works best if the N-
peptide of caspase-7 is removed. During apoptosis, this short 23-amino acid segment is 
clipped by caspase-3 prior to caspase-7 activation by the initiators, at least in some cells 
(31), although the involvement of other caspases have not been completely ruled out. 
We favor a simple model in which the highly acidic N-peptide (9 Asp/Glu residues, no 
Arg/Lys) shields the basic exosite until it is cleaved. 
Caspase-7 mutants with altered activity toward p23, yet presenting opposite or 
unchanged activity on the peptidic substrate, provide an important structural constraint 
on the positioning of the substrate to the enzyme. In our model (Fig. 5D), the core of the 
substrate sits in close proximity to the back of the P4 substrate binding pocket. A second 
constraint is the requirement for the cleavage site to sit in the substrate-binding pocket. 
In the case of p23, the length of the C-terminal region spans 49 residues and is 
Boucher et al. 2012 
 
 8 
unstructured, (33) which theoretically allows it to reach either catalytic center. However, 
in the model we proposed, the C-terminal binds the closest active site. This arrangement 
is analogous to the binding of XIAP to caspase-3 (34), with the second baculovirus 
inhibitory repeat (BIR2) positioning itself behind the catalytic site and extending its N-
terminus over the catalytic cleft, but in a reverse orientation in this particular case. 
Probably the most interesting feature of our model is that it raises the possibility of a 
crossed substrate presentation, i.e., the NTD of one catalytic unit provides the exosite 
for the substrate cleaved by the other catalytic unit within a dimer (Fig. 5D). However, 
the segment following the basic motif also allows all interactions to take place on the 
same catalytic unit (direct substrate presentation). It is not certain that the model we 
have just outlined applies to PARP because this protein has six independently folded 
domains [reviewed in (35)], thus offering several surfaces for exosite binding. 
Furthermore, Germain et al. demonstrated that caspase-7, but not caspase-3, has 
affinity for the polyanionic ADP-ribose polymer (PAR) synthetized by PARP as part of its 
auto-modification activity (17). The protocol we used to extract PARP was not designed 
to preferentially select modified or unmodified PARP, but may have a bias toward a 
particular form. We did not use inhibitors of PAR formation and PAR glycohydrolase, 
and the protocol does not explicitly preserve the energy required for PAR synthesis. 
Consequently, we favor a model of interaction with PARP itself and not PAR. This is 
further supported by the ability of the exosite to promote p23 proteolysis, which is not 
modified, but we cannot rule out an important contribution by PAR to the interaction. 
Another difference may come from the screening of the caspase-7 mutant library with 
PARP that did not result in the identification of any determinant other than the NTD, 
although the strong interaction with the NTD could have masked other determinants. If 
the proposed model for p23 interaction also holds for PARP, the exosite would bind to 
the second zinc-finger domain, which precedes the cleavage site. 
The interaction of the NTD with p23 is not as strong as it is with PARP. The 
reason for this is unknown, but it is tempting to speculate that the additional interactions 
provided by the residues we identified on the catalytic domain of caspase-7 also 
contribute to p23 cleavage efficiency, thus removing the requirement for strong binding 
to the NTD. Furthermore, we estimated that p23 is cleaved at least 100 times more 
slowly than PARP, which cast some doubt on the relevance of its cleavage during 
apoptosis, at least in the early phase. The simplest answer to explain the large 
difference in proteolysis rates of PARP and p23 probably resides in the more efficient 
exosite for PARP (this study) compounded with the favorable aspartate residue at the 
P4 position of the cleavage site compared to a proline in p23 (7). Other determinants 
such as secondary and tertiary structures surrounding the cleavage site may also 
contribute to the difference observed. The p23 promotes ATP hydrolysis and may also 
specify the client protein repertoire of Hsp90, thus potentially affecting the many 
activities performed by this system. Furthermore, if many of the roles performed by its 
yeast ortholog Sba1 are conserved in humans, p23 would play a pivotal role in DNA 
repair, which is reminiscent of the crucial role of PARP in genome maintenance. 
Consequently, its proteolysis could have widespread consequences on cellular 
functions. 
Our findings raise the attractive possibility that caspases could use different 
exosites to achieve their apoptotic and non-apoptotic functions. This multiplicity of 
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exosites is not unheard of, as some proteases, such as thrombin, use many exosites to 
bind different substrates and inhibitors. It is likely that other caspases have evolved 
different exosites to achieve proficiency in their roles during apoptosis and the ever-
growing list of non-apoptotic roles of these enzymes. 
 
Materials and Methods 
Plasmids. For mammalian cell expression, caspases were expressed with a C-terminal 
Flag epitope using the pcDNA3 plasmid. The various mutants were generated using 
standard PCR techniques. A short hairpin RNA construct in pSuper plasmid targeting 
caspase-7 was created using the following sequences: 5’-
gatccccAGACCGGTCCTCGTTTGTAttcaagagaTACAAACGAGGACCGGTCTttttta-3’ 
and 5’-
agcttaaaaaAGACCGGTCCTCGTTTGTAtctcttgaaTACAAACGAGGACCGGTCTGGG-3’ 
(capital letters denote the interfering sequence). Caspase-7 resistance to the shRNA 
was provided by silent mutations of the recognized sequence (underlined nucleotides). 
Cell culture and transfection. AD-293 cells were transfected using Lipofectamine 2000 
reagent. High-level expression was achieved using 2-4 µg (35/60-mm dishes) of plasmid 
DNA, whereas lower levels were obtained using 0.25-0.5 µg of the caspase DNA and 
empty plasmid to 3-4 µg. 
Caspase expression, purification and characterization. Recombinant caspase 
proteins were expressed as C-terminal His6-tagged proteins in the bacteria and purified 
using immobilized metal affinity chromatography (IMAC) (26). All enzymes were active 
site-titrated using the irreversible inhibitor Z-VAD-fmk. The kinetic parameters (kcat and 
KM) were determined using the fluorogenic substrate AcDEVD-Afc (36). 
Cleavage assays. Cellular extracts containing PARP, ICAD or p23 were prepared from 
clonal MCF-7 cells stably expressing an anti-caspase-7 shRNA (see above) to reduce 
potential interference by endogenous executioner caspases. Cells were grown to 
confluence, washed, and harvested in PBS/EDTA/EGTA. Extracts were prepared in ice-
cold buffer [50 mM HEPES (pH 7.4), 150 mM NaCl, 1% NP-40] and incubated on ice for 
30 min. The soluble material (detergent extract) was recovered by centrifugation at 
7,000 x g for 10 min and kept at -80˚C in small aliquots. A 20- to 30-µl reaction mixture 
containing detergent extract (1.5-3.5 mg ml-1) was used with 0.5-1.0 nM active-site-
titrated protease in caspase buffer at 37˚C for 30-60 min. Assays that used recombinant 
caspase-9 or p35-C2A were performed similarly by substituting the extracts with purified 
proteins. 
GST (glutathione-S-transferase) pull-down assay. Residues 24-62 from caspase-7 
were expressed in E. coli as a GST-fusion protein, and purified using glutathione resin. 
Pull-down assays were performed in caspase buffer containing 2 mM DTT 
[supplemented with the general protease inhibitors and 10 µM AcDEVD-CHO] using ~10 
µg (~3 nmoles) of bound protein, 15 µl of resin and 200 µg of MCF-7sh7 detergent extract 
(1 µg ml-1) overnight at 4˚C. Post-pull-down supernatant and bound proteins were 
analyzed by immunoblotting. 
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Hypotonic extracts. Extracts from transfected 293sh7 cells were prepared as described 
elsewhere (3). Caspases activation was programmed by the addition of 1 µM horse cytc 
and 1 mM dATP to 40 µl of extracts and 20 µl of extracts as a source of PARP. 
Ectopically expressed caspase-7 levels were adjusted using extracts from empty 
plasmid-transfected cells. 
Recombinant p23 and fluorescein labeling. The p23 cDNA was cloned from a human 
fetal brain cDNA library, expressed using the pGEX system. Proteins were cleaved with 
thrombin. The free amines in p23 were trace labeled using NHS-fluorescein in a 2:1 
fluorescein:p23 molar ratio. Unreacted labeling reagent and buffer were removed using 
a 3,000 molecular weight cut-off spin filter. 
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Figure legends 
 
 
 
Fig. 1. Caspase-7 is better than caspase-3 at cleaving PARP and p23. (A-C) MCF-7sh7 
extracts were incubated for the indicated period of time in the presence of 0, 5, 25, 50 or 
100 nM recombinant caspase-7 or -3 in caspase buffer, then samples were analyzed by 
immunoblotting (IB) using the antibody indicated. (D,E) Recombinant full-length 
caspase-9 (1 µM) or p35-C2A (400 nM) was treated as in (A). Samples were TCA-
precipitated and analyzed by SDS-PAGE. (F) One nanomolar recombinant caspase-3 
or -7 was incubated with immunoprecipitated flag-tagged PARP for the indicated period 
of time. Samples were analyzed as in (A). Closed arrowhead, full-length protein; open 
arrowhead, cleaved fragment. 
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Fig. 2. Caspase-7’s N-terminal domain contains a transferable exosite to promote PARP 
cleavage. (A) The amino acid sequence of the N-terminal domain of caspase-7 and -3 
are presented. Asp23 of caspase-7 or Asp28 of caspase-3 are the P1 cleavage site 
residue of the N-peptide that is removed during apoptosis. Mature caspase-7 and -3 
start at Ala24 and Ser29, respectively. Key residues are underlined including the 
conserved methionine used as a convenient location for NTD deletion or chimera 
design. (B,D,F) MCF-7sh7 detergent extracts were incubated for 30 min in the presence 
of 1 nM of the indicated caspases. Samples were analyzed by immunoblotting using an 
antibody recognizing the N-terminus of PARP. Quantification of PARP proteolysis is 
presented in Supplementary Fig. 2. (C,E) Detergent extracts were incubated for the 
indicated period of time with 2-fold serial dilution of the indicated recombinant enzyme in 
caspase buffer starting at the indicated concentration. PARP hydrolysis rate were 
estimated as described in Materials and Methods. The enzyme concentration at which 
50% of PARP is cleaved (arrow) was used to estimate rates. In (C), the calculated rates 
are 6.2 x 105, <0.2 and 0.8 x 105 M-1s-1 for caspase-7, M45-caspase-7 and caspase-3, 
respectively. In (E), the calculated rates are 6.5 and 22.1 x 105 M-1s-1 for caspase-7 and 
caspase-7:caspase-3 chimera, respectively. 
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Fig. 3. The K38KKK motif is critical to the exosite function. (A-D) MCF-7sh7 detergent 
extracts were incubated for 30 min in the presence of 1 nM of the indicated caspases. 
Samples were analyzed by immunoblotting using an anti-PARP antibody recognizing the 
N-terminus. Proteolysis quantification is presented in Supplementary Fig. 2. 
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Fig. 4. Efficient PARP proteolysis in apoptotic cells depends on the exosite. (A) 293sh7 
cells were transfected with the indicated flag-tagged shRNA resistant caspase-7 cDNAs. 
Lysates were analyzed 24 h post-transfection with the indicated antibodies. (B) Trail 
(200 ng/ml)-induced PARP cleavage in cells expressing non-lethal levels of WT or 
caspase-7AAAA. Samples were harvested after 3 h. All lanes were from the same blot. (C) 
Time-course of Trail-induced PARP cleavage in cells expressing non-lethal levels of WT 
or caspase-7AAAA. (D) Hypotonic extracts from 293sh7 cells reconstituted with low 
amounts of WT or caspase-7AAAA and supplemented with PARP-containing extracts 
were activated with cytc and dATP. fl, full-length; -Npep, caspase-7 lacking the N-
peptide. 
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Fig. 5. The exosite promotes cleavage of p23. (A) Fluorescein-labeled p23 (50 nM) was 
incubated with 40 nM of the indicated caspase for 30 min and was analyzed by 
fluorescence imaging of gels. (B) Same as in (A) with caspases from the 
caspase-7:caspase-3 library (Supplementary Fig. 8). Mutants showing decrease 
(orange arrows) or increase (green arrows) in processing are indicated. Mut8 was 
inactive, therefore not analyzed. (C) Surface model of caspase-7 [PDB: 1F1J (37)] 
presenting the 10 sets of residues identified in (B). The dimeric caspase contains two 
catalytic units, each of them is constituted of a large (blue or gray) and a small (cyan or 
white) subunits. The active site (S) is identified in red. For each mutant, the relative 
specific activity (kcat/KM) versus WT for the fluorogenic substrate and the percentage of 
p23 cleavage are presented. Mut2 lies in a crevasse on the side of the caspase. The 
NTD is attached at the yellow region. (D) Proposed model for the exosite mechanism. i) 
Caspase-3 primes caspase-7 zymogen for activation by removing the negatively 
charged N-terminal peptide, simultaneously uncovering the basic exosite. ii) Then, an 
initiator caspase activates caspase-7 by cleaving the linker that separates the large and 
small subunits. iii) Up to two molecules of substrates bind the caspase dimer, either in a 
direct or in a crossed mode. iv) Exosite binding promotes cleavage of the aspartate-
containing motif by the catalytic site. 
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Detailed Materials and Methods 
Reagents. Specialized chemicals were obtained from the following sources: G418, 
isopropyl-β-D-thiogalactopyranoside (IPTG) and cell culture media from WISENT Inc. 
(Montréal QC, Canada); GelCode blue stain and N-hydroxy-succinimidyl (NHS)-
fluorescein from Thermo Sci. (Rockford IL, USA); glutathione and chelating sepharose 
4B fast flow resins from GE Healthcare (Baie d’Urfe QC, Canada); Trail from Enzo Life 
Sciences (Plymouth Meeting PA, USA); Tropix I-BLOCK from Life Technologies 
(Carlsbad CA, USA); and thrombin, streptavidin-HRP, dATP, digitonin, horse 
cytochrome c and general protease inhibitors from Sigma-Aldrich (St-Louis MI, USA). 
Caspase inhibitors and caspase substrates were obtained from BioMol (Farmingdale 
NY, USA). Other chemicals and molecular biology reagents and enzymes were obtained 
from general sources. 
 
Plasmids. Human caspase-7 (GenBank acc. no. NM_001227) and human caspase-3 
(GenBank acc. no. NM_032991.2) cDNAs were used for all constructs. All recombinant 
caspase proteins were expressed using the pET-23b(+) (Novagen) plasmid as 
previously described. (26) For mammalian cell expression, all caspase-7 and caspase-3 
proteins were expressed using a modified pcDNA3 plasmid that allowed fusion of the 
cDNA to a sequence encoding a Flag epitope following an XhoI restriction site. 
Consequently, all expressed proteins contain a C-terminal ELDYKDDDDK sequence 
and have the native or engineered N-terminus.  
 Truncation mutants for mammalian expression were generated using standard 
PCR and an oligonucleotide encoding a Kozak sequence and a 3’ reverse primer. All 
other mutants were generated by overlapping PCR with a pair of oligonucleotides 
containing the appropriate substitutions and outside primers. Caspase-3/caspase-7 
chimeras were obtained by overlapping PCR with oligonucleotides encompassing the 
chimeric DNA sequence and outside primers. Oligonucleotide sequences are available 
upon request. 
The p23 cDNA was cloned from a human fetal brain cDNA library using a pair of 
oligonucleotides that inserted a 5’ BamHI restriction site and a 3’ XhoI site. The 
amplified cDNA was subcloned into the same sites of the pGEX-KG plasmid for bacterial 
expression. 
 A short hairpin RNA construct targeting caspase-7 was created using the 
following sequences: 5’-
gatccccAGACCGGTCCTCGTTTGTAttcaagagaTACAAACGAGGACCGGTCTttttta-3’ 
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and 5’-
AGCTtaaaaaAGACCGGTCCTCGTTTGTAtctcttgaaTACAAACGAGGACCGGTCTGGG-
3’ (capital letters denote the interfering sequence). Both primers (20 µM each) were 
annealed in annealing buffer [30 mM HEPES-KOH (pH 7.4), 100 mM potassium acetate, 
2 mM magnesium acetate] and ligated into the BglII-HindIII sites of pSuper. (38) 
Caspase-7 resistance to RNA interference was provided by the silent mutations of 3 
nucleotides within the recognition motif of the mature RNAi (underlined in the above 
sequence). 
 
Cell culture and transfection. AD-293 (human embryonic kidney cells; Invitrogen 
caspase, USA) cells were grown in DMEM medium supplemented with 10% v/v FBS, 2 
mM L-glutamine and penicillin/streptomycin. Every three days, the cells were either split 
or provided with fresh medium. MCF-7 cells (human mammary gland adenocarcinoma 
pleural effusion; ATCC), which do not express caspase-3, were propagated in EMEM 
medium supplemented as described for 293Ad cells. MCF-7sh7 stable cells were 
established by selecting transfected cells for 14 days using 0.5 mg ml-1 G418. Clonal cell 
lines were obtained from the stable population using cloning rings or 96-well plate 
seeding (9-11 cells ml-1, 0.1 ml per well). Cells were expanded in the appropriate 
medium and caspase-7 levels were characterized by immunoblotting. 
Cells were transfected with the indicated plasmids using Lipofectamine 2000 
reagent (Invitrogen) according to the manufacturer’s instructions. High-level expression 
was achieved using 2 (6-well plates) or 3-4 (6-cm dishes) µg of plasmid DNA. Lower 
levels of expression were obtained using 0.25-0.5 µg of the caspase plasmid DNA and 
empty plasmid (3-4 µg final quantities). Cells and debris were harvested at 24 h or the 
indicated time later in PBS with 1 mM EDTA/EGTA, pelleted by centrifugation, washed 
in PBS and kept frozen at -80˚C in 10 µl of PBS to facilitate the lysis step. We routinely 
obtained >80% transfection efficiency based on a β-galactosidase assay. 
Caspases were labeled in intact cells with 20 µM biotinyl-VAD-fmk in culture 
media for 1 h at 37˚C. Then, cells were harvested and kept as described above. 
 
Caspase expression, purification and characterization. Recombinant caspases were 
expressed as C-terminal His6-tagged proteins in the BL21(DE3)pLysS Escherichia coli 
strain (Novagen) in 2xYT medium containing 100 µg ml-1 ampicillin at 30˚C for 5-20 h to 
obtain a fully processed active protein. Proteins were purified using immobilized metal 
affinity chromatography (IMAC) as described elsewhere. With the exception of the 
caspase-7 5A4 alanine mutant and the casp3:casp7 chimera, for which protein 
concentrations were estimated based on 80% of the absorbance at 280 nm, all enzymes 
were active site-titrated using the irreversible inhibitor Z-VAD-fmk as described. The 
kinetic parameters (kcat, KM and kcat/KM) were determined by nonlinear regression using 
the Michaelis-Menten equation on the velocity data obtained in caspase buffer [10 mM 
PIPES (pH 7.4), 100 mM NaCl, 10% sucrose, 0.1% CHAPS, 1 mM EDTA and 10 mM 
dithiothreitol] using a substrate concentration range of 0-300 µM AcDEVD-Afc.  
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PARP cleavage assays. Cellular extracts containing PARP were prepared from clonal 
MCF-7 cells stably expressing an anti-caspase-7 shRNA (see above) to reduce potential 
interference by endogenous executioner caspases. Cells were grown to confluence, 
washed with PBS (10 mM Na2HPO4, 1.76 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl), 
harvested in PBS containing 1 mM EDTA and EGTA and recovered by low speed 
centrifugation. The following protocol was adapted from published work (39), and is 
described for a 150-mm plate. We routinely prepared extracts from 8 150-mm plates. 
The cell pellet was resuspended in 0.2 ml of ice-cold solution 1 [50 mM HEPES (pH 7.4), 
150 mM NaCl and 25 µg ml-1 digitonin] and incubated on ice for 10 min. After 
centrifugation at 2,000 x g, the pellet was resuspended by vigorous mixing in 0.2 ml of 
ice-cold solution 2 [50 mM HEPES (pH 7.4), 150 mM NaCl, 1% NP-40] and incubated on 
ice for 30 min. The soluble material (detergent extract) was recovered by centrifugation 
at 7,000 x g for 10 min and kept at -80˚C in small aliquots. The general non-caspase 
protease inhibitors (1 mM 1,10-ortho-phenanthroline, 10 µM E-64, 10 µM leupeptin, 10 
µM 3,4-dichloroisocoumarin, 1µM MG-132) were added to all buffers. The PARP 
cleavage assay was then performed as follows. Unless otherwise mentioned, a 20- to 
30-µl reaction mixture containing detergent extract (1.5-3.5 mg ml-1) was used with 0.5-
1.0 nM active-site-titrated protease in caspase buffer at 37˚C for 30-60 min. 
Assays that used recombinant caspase-9 or p35-C2A were performed similarly by 
substituting the extracts with purified proteins. Proteins were TCA-precipitated and 
analyzed by SDS-PAGE. Flag-tagged PARP protein was produced in AD-293sh7 cells by 
transfection. PARP was recovered by immunoprecipitation using the M2 anti-flag 
antibody, protein A/G beads and eluted using 100 µg/ml-1 flag peptide. Proteins were 
dialyzed to remove excess flag peptide. 
PARP hydrolysis rate were estimated using the relation p = 1-ekEt which 
correlates the proportion of substrate cleaved to enzyme concentration (E), time (t) and 
cleavage rate (k). Importantly, the same extracts preparation containing PARP was used 
for all determinations, which allows relative comparison. 
 
GST (glutathione-S-transferase) pull-down assay. Residues 24-62 from WT 
caspase-7 were expressed in BL21(DE3) E. coli as a GST-fusion protein using the 
pGEX-KG system. Proteins were purified using glutathione resin in PBS containing 1% 
Triton X-100. Pull-down assays were performed in caspase buffer containing 2 mM DTT 
[supplemented with the general protease inhibitors listed above and 10 µM AcDEVD-
CHO] using ~10 µg (~3 nmoles) of bound protein, 15 µl of resin and 200 µg of MCF-7sh7 
detergent extract (1 µg ml-1) overnight at 4˚C. The resin was washed 3 times with 
caspase buffer, and the proteins were analyzed by immunoblotting. The post-pull-down 
supernatant was also analyzed to estimate the pull-down efficacy. 
 
Hypotonic extracts. Extracts from transfected AD-293sh7 cells were prepared as 
described elsewhere (3) in a PIPES buffer [20 mM PIPES (pH 7.4), 20 mM KCl, 5 mM 
EDTA, 2 mM MgCl2 and 2 mM dithiothreitol]. Caspases activation was programmed by 
the addition of 1 µM horse cytochrome c and 1 mM dATP to 40 µl of extracts and 20 µl 
of dialyzed (8,000 molecular weight cut-off membrane; Spectrum Lab. Inc, Rancho 
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Dominguez CA, USA) detergent extracts as a source of PARP. Ectopically expressed 
caspase-7 levels were adjusted using extracts from empty plasmid-transfected cells. 
Caspase-3 and -7 activity was measured using 200 µM of the chromogenic substrate 
Ac-DEVD-pNA. 
 
Recombinant p23 and fluorescein labeling. Full-length p23 was expressed in 
BL21(DE3) E. coli as a GST fusion protein using the pGEX-4T-1 system (GE 
Healthcare). Proteins were purified in PBS containing 1% Triton X-100 using glutathione 
resin, washed with PBS and cleaved with thrombin (10 U per ml of resin) at 4˚C for 16 h. 
The free amines in purified p23 were trace labeled using NHS-fluorescein in a 2:1 
fluorescein:p23 molar ratio. Unreacted labeling reagent and buffer were removed using 
a 3,000 molecular weight cut-off Amicon Ultra spin filter (Millipore). 
 
SDS-PAGE and immunoblotting. Cell extracts were prepared by boiling PBS-washed 
cells for 10 min in 50 mM Tris (pH 7.4), 4 M urea and 1% SDS. Clarified lysates were 
resolved on continuous SDS polyacrylamide gels using the ammediol buffer system and 
transferred to polyvinylidene difluoride (PVDF) membrane in 10 mM CAPS (pH 11) and 
10% methanol at constant current (0.4 A for 40-60 min). The ensuing blots were 
processed for immunoblotting with the indicated antibodies and the corresponding HRP-
conjugated secondary antibodies (1:7,500; GE Healthcare) and Luminata Crescendo 
Western HRP substrate (Millipore). The chemiluminescence was monitored using a 
VersaDoc 4000MP imaging system (BioRad), and the quantification analyses were 
performed on the non-saturated raw images using the QuantiOne software (BioRad). 
The following primary antibodies were used: caspase-7 (1:1,1500; 9492; Cell Signaling 
Technologies), M2 anti-Flag (0.5 µg ml-1; F-3165; Sigma-Aldrich); Hsp90 (0.025 µg ml-1; 
610419; BD Transduction Lab.), ICAD (0.17 µg ml-1; PX023A; Cell Sciences); p23 
(1:2,000; MA3-414; Thermo Scientific); and PARP [(C-terminus; 1:7,500; 556362; BD 
Pharmingen) or (N-terminus; 1:7,500; ALX-804-211; Enzo Life Sci.)]. To detect 
biotinylated proteins, samples were prepared, resolved on SDS-PAGE and transferred 
onto PVDF membrane as described above, membranes were blocked using 0.2% 
Tropix I-BLOCK in PBS and revealed using streptavidin-HRP (0.2 µg ml-1) and HRP 
substrate as above. Broad Range or dual color Precision Plus protein standards were 
used.  
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Supplementary table and figure legends 
 
 
Table SI Kinetic parameters on AcDEVD-Afc substrate of wild-type and mutant 
caspases used in this study. 
       
Caspases KM (µM) ± kcat (s-1) ± kcat/Km (s-1M-1) ± 
WT and chimeric caspases 
Caspase-7 1 31.9 4.6 3.4 0.2 1.1 x 105 0.2 x 105 
Caspase-3 1 8.8 2.3 5.2 0.4 5.9 x 105 2.0 x 105 
Casp3:casp7 1 21.8 4.3 7.8 0.5 3.6 x 105 0.9 x 105 
Casp7:casp3 1 12.5 2.3 9.3 0.5 7.4 x 105 1.7 x 105 
Caspase-7 2 
(AcPEVD-Afc) 
    3.9  
Caspase-3 
(AcPEVD-Afc) 
95.1 7.7 0.2 0.0 1.9 x 103 1.6 x 102 
Deletion mutants 
M23 3 
M28 
68.3 
40.8 
3.8 
8.4 
9.5 
14.7 
0.2 
1.2 
1.4 x 105 
3.5 x 105 
n/a 
1.1 x 105 
M32 32.2 2.2 5.1 0.1 1.6 x 105 1.4 x 104 
M36 51.1 3.7 5.6 0.2 1.1 x 105 1.2 x 104 
M40 26.2 2.0 6.0 0.2 2.3 x 105 2.5 x 104 
M45 1 20.6 4.4 2.8 0.2 1.3 x 105 0.4 x 105 
Tetra-alanine mutants 
1A4 39.8 3.1 3.5 0.1 8.8 x 104 1.0 x 104 
2A4 29.7 3.3 3.5 0.1 1.2 x 105 1.6 x 104 
3A4 24.2 2.9 5.6 0.2 2.3 x 105 3.6 x 104 
4A4 22.3 1.0 4.7 0.1 2.1 x 105 1.4 x 104 
5A4 36.8 1.6 6.65 0.1 1.8 x 105 1.0 x 104 
Single alanine mutants 
D23A 3 68.7 4.5 9.5 0.2 1.4 x 105 n/a 
S37A 37.5 2.4 4.4 0.1 1.2 x 105 1.0 x 104 
K38A 35.7 1.4 4.3 0.1 1.2 x 105 0.7 x 104 
K39A 36.6 1.5 3.9 0.1 1.1 x 105 6.7 x 103 
K40A 29.8 1.6 2.9 0.1 9.7 x 104 6.8 x 103 
K41A 47.8 2.9 4.1 0.1 8.6 x 104 7.0 x 103 
KKKK mutants 
AAAA  31.3 2.0 6.1 0.1 2.0 x 105 5.2 x 104 
KAAK 41.1 2.5 8.9 0.2 2.2 x 105 7.7 x 103 
KEEK 13.5 0.9 6.2 0.1 4.6 x 105 3.8 x 104 
KEKK 25.1 1.1 4.6 0.1 1.8 x 105 1.1 x 104 
Library 
Mutant 1 36.6 3.6 1.2 0.1 3.4 x 104 4.7 x 103 
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Mutant 2 41.8 1.7 1.1 0.0 2.6 x 104 1.4 x 103 
Mutant 3 31.6 1.6 2.3 0.0 7.2 x 104 5.0 x 103 
Mutant 4 81.8 7.0 4.6 0.2 5.6 x 104 6.8 x 103 
Mutant 5 35.9 1.9 4.1 0.1 1.2 x 105 8.4 x 103 
Mutant 6 81.2 8.1 13.4 0.1 1.7 x 105 3.0 x 104 
Mutant 7 32.0 4.4 1.3 0.1 4.0 x 104 7.4 x 103 
Mutant 8 no detectable activity 
Mutant 9 29.5 1.4 2.4 0.1 8.3 x 104 5.3 x 103 
Mutant 10 39.8 1.6 3.6 0.1 9.1 x 104 5.1 x 103 
Mutant 11 30.2 2.3 3.3 0.1 1.1 x 105 1.1 x 104 
Mutant 12 31.7 2.3 3.1 0.1 9.9 x 104 9.5 x 103 
Mutant 13 22.4 1.7 2.9 0.1 1.3 x 105 1.0 x 104 
Mutant 14 31.1 1.8 2.8 0.1 8.8 x 104 6.8 x 103 
Mutant 15 29.3 1.1 3.5 0.1 1.2 x 105 6.0 x 103 
Mutant 16 31.7 4.4 2.6 0.1 8.2 x 104 1.5 x 104 
Mutant 17 37.7 2.6 0.7 0.0 2.0 x 104 1.8 x 103 
Mutant 18 76.4 5.4 1.7 0.1 2.2 x 104 2.2 x 103 
Mutant 19 22.8 1.3 6.9 0.1 3.0 x 105 2.3 x 104 
Mutant 20 26.8 3.2 1.9 0.1 7.2 x 104 1.1 x 104 
Mutant 21 39.6 2.6 2.8 0.1 7.1 x 104 6.2 x 103 
Mutant 22 45.8 2.9 3.4 0.1 7.5 x 104 6.4 x 103 
Mutant 23 12.2 1.0 2.1 0.0 1.7 x 105 1.7 x 104 
Mutant 24 54.7 6.2 1.7 0.1 3.1 x 104 5.0 x 103 
Mutant 25 51.6 4.1 3.6 0.1 6.9 x 104 8.2 x 103 
Mutant 26 90.9 6.5 1.4 0.1 1.5 x 104 1.6 x 103 
Mutant 27 18.2 0.8 8.5 0.1 4.6 x 105 2.6 x 104 
Mutant 28 47.5 3.4 2.3 0.1 4.8 x 104 4.8 x 103 
Mutant 29 10.6 1.1 3.7 0.1 3.5 x 105 4.6 x 104 
 
1: Kinetic parameters were compiled from at least 3 independent determinations and 
standard errors are reported. 
2: Kinetic parameters were obtained in pseudo-first order conditions because the KM is > 
100 µM. 
3: Taken from Denault, J.-B. & Salvesen, G.S. (2003) Human Caspase-7 Activity and 
Regulation by Its N-terminal Peptide. J Biol Chem 278, 34042-50. n/a, not available. 
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Fig. S1. Short hairpin RNA-mediated repression of caspase-7 expression in clonal 
MCF-7 and AD-293 cells. (A) Clonal MCF-7 cell lines were generated using empty 
pSuper (clones B8 or B3) or pSuper containing a short hairpin RNA against caspase-7 
(other clones) as described in Materials and methods. Clones were analyzed by 
immunoblotting with anti-caspase-7 and anti-hsp90 antibodies. Caspase-7 expression 
repression was normalized with the control proteins and compared to the parental cells. 
Clone C8 was chosen to prepare cellular extracts. (B) Clonal AD-293 cell lines were 
generated using empty pSuper (first lane) or pSuper containing the same short hairpin 
RNA as in (A). Clones were analyzed as in (A) using a panel of antibodies (2 
independent actin quantifications). Clone 32 was chosen. 
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Fig. S2. Quantification of PARP proteolysis from key panels of Fig. 2 and Fig. 3. Results 
from Fig. 2B,D,F and Fig. 3A,B,C,D from the main document were further analyzed to 
determine the percentage of PARP proteolysis. The intensity of the 116-kDa band was 
quantified using Quantity One software (BioRad) from non saturated exposure acquired 
on a VersaDoc 4000MP imager. Values are percentages of cleavage compared to the 
untreated sample figuring on each blots. Blots are labeled as in the manuscript. 
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Fig. S3. Bacterial expression and autoactivation of wild-type caspase-3 and -7 and 
chimeric caspases. The indicated caspase were analyzed on poly-acrylamide gel and 
visualized using GelCode blue staining reagent. Schematics of proteins obtained after 
N-peptide removal and cleavage at activation sites are presented on the right. 
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Fig. S4. Caspase-3 or -7’s NTD does not confer preference for ICAD cleavage. 
Detergent extracts were incubated for 15 min in the presence of 10 nM of the indicated 
caspase in caspase buffer, and then analyzed by immunoblotting using an anti-ICAD 
antibody. The asterisk indicates a non-specific band recognized by the antibody and 
serves as a loading control. Closed arrowhead, full-length protein. 
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Fig. S5. Caspase 7’s NTD binds PARP. Ten µg of GST, GST-NTD or GST-NTDAAAA on 
beads were incubated with 200 µg (1 mg ml-1) of MCF-7sh7 extract for 16 h at 4˚C. Pull-
down proteins (top) and equal proportion of post pull-down supernatant (middle) were 
analyzed by immunoblotting with the indicated antibodies. Blots were quantified to 
determine pull-down and depletion efficacy and are presented as percentage of total 
PARP protein used in each samples. SDS-PAGE analysis of GST proteins is presented 
(bottom). 
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Fig. S6. Labeling of caspase-7 and caspase-7AAAA in intact cells. Twenty-four hours 
post-transfection, cells as in Fig. 4A were incubated for 1 h with 20 µM of the cell 
permeable biotinyl-VAD-fmk irreversible caspase inhibitor. Extracts were prepared and 
analyzed by immunoblot using an anti-PARP antibody or using streptavidin-HRP to 
revealed biotinylated (active) caspase-7 (bioblot). Closed arrowhead, full-length protein; 
open arrowhead, cleaved fragment. 
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Fig. S7. FITC-labeled and unlabeled p23 are cleaved as efficiently by caspase-7. 
Unlabeled or fluorescein labeled purified recombinant p23 (50 nM) was incubated for 30 
min with 2-fold serial dilution of recombinant caspase-7 in caspase buffer starting at a 
caspase concentration of 40 nM. Samples were analyzed by fluorescence imaging (top) 
or immunoblotting (bottom) using an anti-p23 antibody. It is noted that no more than a 2-
fold difference in cleavage efficiency was observed. Closed arrowhead, full-length 
protein; open arrowheads, cleaved fragments. 
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Fig. S8. Rational design of the caspase-7:caspase-3 mutant library. Alignment of 
caspase-7 and caspase-3 primary sequence. Boxed residues correspond to mutants in 
which amino acids from caspase-3 were substituted in caspase-7. Italicized and 
underlined residues were not mutated because they are buried into the structure. The 
catalytic cysteine and histidine along with the methionine 62, which was used to create 
chimeric caspases, and methionine 45 are indicated. The N-terminal residue of the 
mature form of each caspases resulting from the removal of the N-peptide is circled. A 
red box indicates the tetrabasic patch. The linker that separates the large and small 
subunit is shadowed and was left unchanged. 
